Bone Abstracts

A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 1–84-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not d...

Background: The optimal level of 25-hydroxyvitamin D2 (25(OH) D) for a healthy bone is not clear, nor the effects of treatment with vitamin D. Few previous studies have measured treatment effect on BMD in young deficient individuals.Materials and methods: A treatment group of vitamin D deficient immigrant women and a control group of ethnic Swedish women were recruited during pregnancy. A treatment of 800–1600 IU cholecalciferol and 500–1000 mg...

Polyphosphates (polyPs) are inorganic phosphate chains found in many cell types with higher concentrations in bone cells. As a source of inorganic phosphate (Pi) and an effective calcium reservoir due to chelation, PolyPs enable total Ca2+ and PO42− concentrations above those required for apatite saturation. Alkaline phosphatase (ALP) cleaves Pi from polyP, thus polyPs may be involved in apatite mineralization.Aim: ...

Objective: To find whether treatment with cholecalciferol and calcium in a group of vitamin D deficient women is associated with changes in muscular function, musculoskeletal pain, and fatigue.Design: Prospective interventional cohort study.Sample: A study group of 25 post partum women recruited and diagnosed with hypovitaminosis D during pregnancy.Setting: The study group was recruited 2006–2009 at two ...

Recent studies confirmed the role of WNT16 in bone mineral density (BMD), bone strength and fracture risk. These findings made WNT16 interesting for further genetic and functional studies to clarify its effect on osteoporosis related parameters.A WNT16 candidate gene association study was performed in men from the Odense Androgen Study (OAS). Five tagSNPs and one multimarker test were selected for genotyping to cover most of th...

Introduction: Aromatase inhibitors (AI) used as adjuvant treatment of hormone-sensitive breast cancer reduce the level of circulating estrogen and cause accelerated bone loss. The aim of this study is to investigate the prevalence of osteoporosis in women with breast cancer and the effect of chemotherapy on the risk of osteoporosis.Methods: Three hundred and sixty women with hormone-sensitive breast cancer who were scheduled to start treatment with AI we...

The R-spondins are a family of four small, secreted agonists of the Wnt signaling pathway. Growing evidence from both in vitro studies and in vivo models supports the major role of these proteins in the skeletal development processes. In humans, common genetic variation in the RSPO3 gene has been associated with BMD in large scale GWAS study.This study aimed at further investigation of the genetic and functional contributions of the R-s...

Objectives: Two important goals of the Rare Diseases Clinical Research Network Brittle Bone Disorders Consortium (RDCRN BBD) are i) to perform collaborative clinical research in brittle bone disorders including a longitudinal observational study driven by genotypic association and ii) to explore use of the PROMIS tool to provide valid quality of life (QOL) measures in individuals with Osteogenesis Imperfecta (OI). This work has been motivated by the fact that all current outco...

Objectives: Ghrelin is an orexigenic hormone produced by the stomach that reflects body weight changes and stimulates GH secretion. Recently, it has been shown to be associated with bone metabolism and eating behaviour. The underlying pathophysiology of adolescent idiopathic scoliosis (AIS) refers to possible abnormal bone development. AIS patients also frequently present with low BMI level.Eating behavioural disorders, endocrine disorders, abnormal grow...

Objectives: Bisphosphonates are frequently used in children with skeletal disorders, however optimal dosing and regimens are unknown. Early treatment focused on pamidronate (PAM), a second-generation formulation, however use of zoledronate (ZOL), a more potent third-generation bisphosphonate, has recently increased due to shorter and less frequent infusions. The objective of this study is to compare short-term safety of ZOL and PAM in a pediatric population.<p class="abste...